Illumina announced it will add 50,000 whole genomes paired with proteomic profiles to the Alliance for Genomic Discovery (AGD), with GSK and Amgen leading the expansion and DeCode Genetics generating the proteomic data. The AGD’s core dataset will grow to about 312,000 genomes after Regeneron Genetics Center joins, making the resource one of the largest integrated genomics‑to‑proteomics collections available to industry members. Illumina said the proteomics data will be generated using its Protein Prep assay based on SomaLogic technology and delivered over the next year. The move follows industry efforts to integrate multiomics with longitudinal clinical records to accelerate target discovery and de‑risk early programs. Existing AGD members include major pharmas such as AbbVie, AstraZeneca, GSK, Merck and Novo Nordisk, which underscores the alliance’s direct relevance to drug target validation and biomarker work. For researchers, paired genome‑to‑proteome datasets enable linking genetic variants to downstream protein changes—critical for identifying actionable biology and pharmacodynamic biomarkers. The expansion signals broader industry investment in population‑scale multiomic resources that can shorten discovery timelines and strengthen human‑genetics‑guided pipelines.